Bliss GVS Pharma Ltd
NSE:BLISSGVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (12.2), the stock would be worth ₹156.86 (42% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 20.9 | ₹269.26 |
0%
|
| 3-Year Average | 12.2 | ₹156.86 |
-42%
|
| 5-Year Average | 12.8 | ₹164.33 |
-39%
|
| Industry Average | 29.2 | ₹375.14 |
+39%
|
| Country Average | 23 | ₹295.29 |
+10%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Bliss GVS Pharma Ltd
NSE:BLISSGVS
|
28.4B INR | 20.9 | 26.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 49.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 19.3 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 14.4 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 16.5 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 12.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 8.3 | 16.6 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
Bliss GVS Pharma Ltd
Glance View
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 750 full-time employees. The company went IPO on 2010-07-26. The firm offers a range of suppositories, tablets, suspensions and injections to various therapeutic segments, including antimalarial, antifungal, dermatological, contraceptive, laxative, anti-hemorrhoidal, antispasmodic, antibiotic, antimicrobial antipyretic, analgesic and anti-inflammatory. The firm's pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatin capsules and syrups. its other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray and petroleum jelly. The firm offers its products under various brands, which include Lonart, Funbact, P-Alaxin, Lofnac, Amoxicillin, Antiderm Extra Plus and Esmazole. Its product portfolio comprises over 250 branded formulations across 20 therapeutic segments.
